Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 658
- Institution
- Institut Gustave Roussy
External Links
Identifiers
- ORCID
- 0000-0002-9747-8419
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.